To understand whether inhibition of the STAT3 pathway could enhance the anti-tumor activity of chemotherapy reagents, we incubated human ovarian cancer cells with several chemotherapy agents, either alone or in combination with ruxolitinib. This evidence concerns the gene STAT3 and ovarian carcinoma.